Relationship between Urinary AD7c-NTP with Cerebral Microbleeds Based on APOE Genotype
1Department of Neurology, Weihai Central Hospital Affiliated to Qingdao University and Weifang Medical College, Weihai, Shandong 264400, China.
Biomed Research International
|October 18, 2021
Summary
Higher urinary Alzheimer-associated neuronal thread protein (AD7c-NTP) levels are linked to lobar cerebral microbleeds (CMBs). This association is particularly strong in individuals with specific apolipoprotein E (APOE) genotypes, suggesting a potential biomarker role for AD7c-NTP in lobar CMBs.
Area of Science:
- Neurology
- Biochemistry
- Genetics
Background:
- Cerebral microbleeds (CMBs) are small hemorrhages in the brain, often associated with neurological conditions.
- Alzheimer-associated neuronal thread protein (AD7c-NTP) is a biomarker investigated in neurodegenerative diseases.
- Apolipoprotein E (APOE) genotypes are known risk factors for various neurological disorders, including those involving CMBs.
Purpose of the Study:
- To investigate the association between urinary AD7c-NTP levels and CMBs.
- To explore the influence of APOE genotypes on this association.
Main Methods:
- 444 patients with acute cerebral infarction were analyzed.
- Urine AD7c-NTP levels were quantified using an enzyme immunoassay kit.
- Patients were categorized based on the presence or absence of CMBs and APOE genotypes.
Main Results:
- An interaction was observed between urinary AD7c-NTP levels and APOE genotypes in patients with lobar CMBs (p=0.01).
- Individuals with APOE ε2+ or ε4+ alleles showed a significantly higher odds ratio (2.95) of lobar CMBs per standard deviation of urinary AD7c-NTP.
- No significant association was found for deep CMBs.
Conclusions:
- Elevated urinary AD7c-NTP levels are associated with lobar CMBs.
- The APOE genotype modifies the relationship between urinary AD7c-NTP and lobar CMBs.
- Urinary AD7c-NTP may serve as a potential biomarker for lobar CMBs, particularly in individuals with specific APOE alleles.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...